Summary for Tradename: NAMENDA
Clinical Trials for: NAMENDA
Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?
Status: Recruiting Condition: Epilepsy
A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
Status: Recruiting Condition: Autism Spectrum Disorders
Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury
Status: Terminated Condition: Traumatic Brain Injury
A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease
Status: Completed Condition: Alzheimer's Disease
Memantine and Intensive Speech-Language Therapy in Aphasia
Status: Completed Condition: Aphasia; Stroke
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
Status: Completed Condition: Autism Spectrum Disorder (ASD); Autism; Autistic Disorder; Asperger's Disorder; Asperger's; Pediatric Autism; Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS); Pervasive Child Development Disorder
Efficacy and Safety of the Use of Memantine for Preserving Cognition in Adult Patients With Epilepsy
Status: Withdrawn Condition: Epilepsy
Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
Status: Completed Condition: Mild Cognitive Impairment; Major Depressive Disorder; Alzheimer's Disease
The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?
Status: Not yet recruiting Condition: Major Depressive Disorder
Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS
Status: Completed Condition: ADHD
Courtesy of ClinicalTrials.org
See more clinical trials for this drug
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Type||RLD||Patent No.||Product||Substance||Delist_Flag||Patent Expiration||Exclusivity Expiration|
|SOLUTION;ORAL||021627||Apr 18, 2005||RX||Yes||5,061,703||<disabled>||<disabled>|
|TABLET;ORAL||021487||Oct 16, 2003||RX||No||5,061,703||<disabled>||<disabled>|
|TABLET;ORAL||021487||Oct 16, 2003||RX||Yes||5,061,703||<disabled>||<disabled>|
|CAPSULE, EXTENDED RELEASE;ORAL||022525||Jun 21, 2010||RX||No||<disabled>||<disabled>|
|The preview shows a limited data set. Complete access is available with a Subscription|
Export unavailable in trial.
Subscribe for complete access.
|memantine hydrochloride||Tablets||5 mg and 10 mg||Namenda||10/16/2007|
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639